What does GoHealth do and what are its main business segments?

What is GoHealth's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for GoHealth year over year?

What guidance did GoHealth's management provide for the next earnings period?

What is the market's earnings forecast for GoHealth next quarter?

What is GoHealth's gross profit margin?

What were the key takeaways from GoHealth’s earnings call?

Did GoHealth beat or miss consensus estimates last quarter?

- **Strategic Pullback**: Intentional 2025 MA volume reduction to preserve cash and focus on 95% retention vs. industry 85%.
- **SNP Leadership**: 15% SNP market share; 70% 2026 SNP products non-commissionable to peers.
- **Growth Engine**: GoHealth Protect up 40% YoY; $32M cash balance with no capital needs.
- **Consolidation Play**: $1B+ M&A pipeline to acquire SNP-focused brokers at 5x EBITDA.

**【CEO Opening Remarks】**
- GoHealth scaled back Medicare Advantage (MA) activity in Q2 2025 due to health plans tightening commissions, eligibility, and benefit structures. 
- Shifted focus to retention, special needs plans (SNPs), and cash preservation.
- Reduced overhead by 30% while investing in AI/automation to improve agent efficiency.
- Secured $40M super-priority term loan and refreshed Board to support strategic flexibility.

**【Q&A Highlights】**
1. **Market Growth Trajectory**: 
   - Health plans prioritizing retention over new enrollment; CMS projects slower MA penetration.
   - SNPs growing 20% YoY as plans reallocate resources to high-margin, stable SNP products.
   - GoHealth expects to return to pre-2025 growth rates with improved margins post-market stabilization.

2. **Strategic Positioning**: 
   - Lead SNP broker with 15% market share; 70% of 2026 SNP products non-commissionable to competitors.
   - GoHealth Protect (non-MA insurance) grew 40% Q3 YoY, offsetting MA decline with stable, recurring revenue.
   - $32M cash balance; no near-term need for additional capital due to disciplined cash management.

3. **Consolidation Opportunity**: 
   - Fragmented broker landscape (1,200+ brokers) creates $1B+ consolidation opportunity.
   - GoHealth uniquely positioned to acquire smaller brokers with strong SNP backbooks.
   - Target 20%+ annualized SNP revenue CAGR through organic growth + M&A.

4. **Retention Strategy**: 
   - 95% retention rate vs. industry average 85% due to focus on confirming existing plans.
   - Agents incentivized to service existing members rather than pursue new sales.
   - AI-powered PlanFit tool automates SNP eligibility checks, reducing agent ramp time to 2 weeks.

**【Financial Performance】**
- Q3 2025: 
   - SNP revenue $120M (up 15% YoY)
   - GoHealth Protect revenue $80M (up 40% YoY)
   - Total revenue $200M (-10% YoY)
   - Adjusted EBITDA $(10M) vs. $(20M) prior year
   - Cash burn $5M/Qtr (vs. $15M pre-scaling back)

GoHealth, Inc. (GOCO) Q3 2025 Earnings Call Transcript

- **$115M Capital Raise**: Secured new term loan with $250M M&A debt basket, enabling strategic acquisitions in fragmented Medicare market.
- **Governance Refresh**: 3 new board members and Transformation Committee to drive capital structure optimization.
- **GoHealth Protect Growth**: $8M Q2 revenue, meeting expectations; scaling life insurance product with agent redeployment.
- **AEP Readiness**: Cautious approach due to health plan uncertainty, but positioned to capitalize on market dynamics.
- **Share Dilution**: Issued 4.7M shares to lenders, aligning incentives with long-term value creation.

**【CEO Opening Remarks】**
- Secured $115M superpriority senior secured term loan facility ($80M new money, $35M existing revolving loans rolled up), providing financial flexibility for M&A and AEP preparation.
- Appointed 3 new board members and established a Transformation Committee to evaluate capital structure and strategic opportunities.
- Removed going concern status; expects to record intangible asset impairment in Q2 10-Q filing.
- $250M debt basket approved for acquisitions, aligning with lender support for consolidation in fragmented Medicare market.

**【Q&A Highlights】**
- **Covenants Comparison**: Replaced multiple covenants with a single minimum liquidity covenant, offering greater operational flexibility.
- **M&A Strategy**: Prioritizes acquisitions with contract assets, talent, and product diversification; $250M debt basket available for transactions.
- **GoHealth Protect Performance**: Generated $8M in Q2 revenue, meeting expectations; focuses on scaling through agent training and technology integration.
- **Regulatory Impact on AEP**: Health plans showing mixed signals on stability; expects disruptive market dynamics similar to prior years.
- **Share Dilution**: Issued 4.7M Class A shares to lenders, aligning incentives with long-term success; interest rate on new money is SOFR + 550bps.
- **CAC and Revenue Trends**: Q2 CAC elevated due to Medicare Advantage pullback; expects efficiency improvements in future quarters as GoHealth Protect scales.


GoHealth (GOCO)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 19% YoY to $221M, driven by 64% captive agency submission growth vs. 24% agent headcount expansion.
- **Profitability Improves**: Adjusted EBITDA surges 56% to $42M, 18% cost per submission reduction, and 12% faster enrollments via AI tools.
- **New Product Momentum**: GoHealth Protect life insurance suite launched, targeting 50%+ Medicare-eligible without coverage, with agents already 15% licensed for life insurance.
- **Market Disruption Expected**: CMS 5.06% MA revenue hike and 10.72% commission boost contrast with Q2/Q3 SEP disruption from health plans pulling back on growth, creating AEP 2025 shopping opportunities.
- **Cash Flow Management**: Negative Q1 cash flow ($12.4M) due to agency mix, but GoHealth Protect's non-agency-like cash dynamics to reduce seasonality.
- **Regulatory Risk**: DOJ intervenes in 7-year-old qui tam lawsuit; GoHealth denies FCA/Anti-Kickback claims but faces potential litigation distraction.

**【CEO Summary Section】**
- Q1 2025 revenue reached $221 million, a 19% year-over-year increase, driven by captive agency submissions growing 64% YoY with only 24% agent headcount growth.
- Adjusted EBITDA rose to $42 million (56% YoY), fueled by 18% reduction in direct operating costs per submission and AI-driven efficiency improvements (12% faster enrollment handle times).
- Launched GoHealth Protect, a life insurance suite targeting Medicare-eligible consumers without coverage, with early agent adoption and 15% YoY sales per submission decline due to agency/non-agency mix shift.
- PlanFit checkups grew 27% YoY, retaining 15,000 consumers in existing plans, while MyGoHealth platform streamlined consumer profiles and enrollment workflows.
- CMS announced 5.06% Medicare Advantage revenue increase and 10.72% broker commission hike, supporting long-term growth despite Q2/Q3 SEP disruption expectations.

**【CFO Financial Commentary】**
- GAAP net loss narrowed to $9.8 million (vs. $12.5M prior year), with adjusted EBITDA up 56% to $42.1 million.
- Commissions receivable reached $1.06 billion (19% YoY), reflecting agency model scalability.
- Negative cash flow ($12.4M) due to agency/non-agency mix shift, offset by GoHealth Protect's non-agency-like cash dynamics.
- Focus on capital discipline, evaluating debt structure optimization while maintaining $22 million cash balance.

**【Q&A Highlights】**
- GoHealth Protect: 15% of agents hold life insurance licenses; testing inbound/outbound marketing with higher conversion rates. Expected to reduce seasonality and lower CAC through multi-product engagement.
- AEP 2025 outlook: Health plans pulling back on commission-eligible products amid margin challenges, likely driving more consumer shopping during Q4 AEP.
- ETQ acquisition integration: 25% YoY agent growth with ETQ agents contributing to captive team efficiency. No separate tracking of ETQ submissions.
- Regulatory risk: U.S. DOJ intervened in 7-year-old qui tam lawsuit alleging FCA/Anti-Kickback violations. GoHealth denies claims, but case may delay capital structure discussions.
- Cash and debt: $22M cash, no specific debt guidance, focusing on operational efficiency over external financing.
- Customer behavior: Volatile markets increase plan-fit checkups (27% YoY growth), with 15,000 consumers retaining plans despite disruptions.

GoHealth (GOCO)-13 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 revenue up 41% to $389M, driven by 67% submission growth and 27% CAC reduction.
- **Operational Excellence**: 82% captive agent growth, 72% PlanFit CheckUp engagement, and 170% e-TeleQuote submissions highlight execution strength.
- **2025 Outlook**: Cautious optimism for first three quarters amid CMS MA growth and strategic PlanFit Save expansion.
- **Financial Health**: $120M annual EBITDA, successful debt refinancing, and $1.1B commissions receivables reflect strong partner alignment.
- **Strategic Focus**: Prioritizing Medicare engagement, cost efficiency, and high-ROI investments for sustainable growth.

**【CEO Summary Section】**
- Q4 2024 revenue reached $389 million, a 41% year-over-year increase, driven by 67% higher submissions (481,000) and 27% lower direct operating cost per submission ($501). Adjusted EBITDA grew 107% to $118 million.
- Operational highlights include 82% submission growth from captive agents (via e-TeleQuote integration) and 25% increase from external partners. Agent handle time improved 8.6%.
- PlanFit CheckUp engagement rose 72%, with 29,000 consumers reaffirmed in their current plans. e-TeleQuote delivered 54,000 submissions, 170% YoY growth.
- 2025 outlook: Cautious optimism for first three quarters amid favorable market dynamics, with CMS 4.3% MA revenue growth and 7.7% broker commission hike.

**【CFO Financial Commentary】**
- Full year 2024 revenue: $798.9 million (+9% YoY), Adjusted EBITDA: $120.3 million (+60% YoY). Q4 cash flow from operations: -$21.6 million (vs. -$130.7 million prior year).
- Completed $475 million term loan refinancing at SOFR +7.5%, reducing interest costs. LTV model incorporates comprehensive risk assessment.
- Commissions receivables: $1.1 billion at year-end, reflecting strong partner relationships.

**【Q&A Key Takeaways】**
- **CAC Efficiency**: Direct cost per submission down to $501 (from $688), with 82% captive agent growth. 2025 CAC trends dependent on market disruption levels.
- **2025 AEP Outlook**: Less disruption than 2024, but favorable dynamics remain. GoHealth's targeted marketing and PlanFit Save will mitigate risk.
- **Balance Sheet Strategy**: Exploring capital optimization (e.g., receivables securitization) to reduce cost of capital while maintaining debt discipline.
- **Long-term Growth**: Focus on Medicare engagement (PlanFit Save, Encompass) before expanding beyond MA. 2025 investments will prioritize high ROI opportunities like agent productivity and tech enablement.

Actual	-0.3	0.3	6.3	-0.3	-1.8	-2.7	-20.25	-1.8	-5.25	-3.45	-7	-1.12	-3.27	-2.61	-0.22	-1.04	-2.7	0.46	1.56	-0.52	-5.1	-11.8
Forecast	-0.5357	-0.2226	7.0833	-0.0643	-0.7327	-1.2643	3.1403	-1.2693	-3.0536	-4.3053	1.3299	-1.582	-2.9182	-2.7441	2.1178	-0.9868	-2.6073	-3.045	0.967	-0.3433	-2.5003	-2.213
Surprise	+44.00%	+234.77%	-11.06%	-366.56%	-145.67%	-113.56%	-744.84%	-41.81%	-71.93%	+19.87%	-626.36%	+29.20%	-12.06%	+4.89%	-110.39%	-5.39%	-3.56%	+115.11%	+61.32%	-51.47%	-103.98%	-433.21%

GOCO

GOCO fundamentals

GOCO Q3 2025 Earnings

Earnings Call

You can ask Aime

GOCO

GOCO fundamentals

GOCO Q3 2025 Earnings

Earnings Call

GOCO Earnings Call Summary for Q3/20258:00 AM on Nov 13, 2025

GOCO Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

GOCO Earnings Call Summary for Q1/20258:00 AM on May 13, 2025

GOCO Earnings Call Summary for Q4/20248:00 AM on Feb 27, 2025

GOCO Earnings Call Summary for Q3/20248:00 AM on Nov 7, 2024

You can ask Aime